Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $130 from $138 and keeps an Outperform rating on the shares. The firm said steady progress continues even if it is masked in the short-term.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Reports Strong 2024 Financial Performance
- ZBH Upcoming Earnings Report: What to Expect?
- Starbucks reports Q1 beat, Frontier proposes Spirit combination: Morning Buzz
- BofA moves to No Rating on Paragon 28 after Zimmer Biomet deal
- Treace Medical ‘a rarer asset’ after Zimmer buys Paragon 28, says Lake Street